Promotional price valid on web orders only. Your contract pricing may differ. Interested in signing up for a dedicated account number?
Learn More
  1. Home
  2. Products
  3. 01001360

CERILLIANT™ Felbamate Solution, 2.0 mg/mL in Methanol, Sold by MilliporeSigma™ Supelco™

Catalog No. 01001360 Shop All MilliporeSigma Supelco Products
Change view
Click to view available options
Quantity:
1 mL
1 product options available for selection
Product selection table with 1 available options. Use arrow keys to navigate and Enter or Space to select.
Catalog No. Quantity
01-001-360 1 mL
Use arrow keys to navigate between rows. Press Enter or Space to select a product option. 1 options available.
1 options
Catalog No. 01-001-360 Supplier MilliporeSigma Supelco Supplier No. F0291ML
 Restricted Item
Add to Cart
Add to Cart

missing translation for 'validMainframeMsg'

Description

Certified reference material

Felbamate is an antiepileptic drug used for the treatment of epilepsy, partial seizures in adults, and partial and generalized seizures associated with Lennox-Gastautsyndrome in children. The drug has a narrow therapeutic range and carries an increased risk of fatal aplastic anemia and/or liver failure. This certified solution standard is suitable as starting material for calibrators or controls for a variety of LC/MS or GC/MS applications such as forensic analysis, clinical toxicology and therapeutic drug monitorin.
TRUSTED_SUSTAINABILITY

Specifications

CAS 67-56-1, 25451-15-4
Linear Formula C11H14N2O4
UN Number UN 1230 - class 3 - PG 2 - Methanol
Concentration 2.0 mg/mL in methanol
Formula Weight 238.24
Packaging Ampule
Quantity 1 mL
Flash Point 9.7°C (49.5°F) - closed cup

CERILLIANT is a registered trademark of Cerilliant Corporation

Product Title
Select an issue

By clicking Submit, you acknowledge that you may be contacted by Fisher Scientific in regards to the feedback you have provided in this form. We will not share your information for any other purposes. All contact information provided shall also be maintained in accordance with our Privacy Policy.